Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594070 · ClinicalTrials.gov registry record · Phase 4
Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy
A Phase 4 study, sponsored by The University of Texas Medical Branch, Galveston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT04594070: Clinical Trial Phase 4 study, sponsored by The University of Texas Medical Branch, Galveston.
NCT04594070 is a Phase 4 study that was terminated before completion, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04594070, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Medical Branch, Galveston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The target population for our study is pregnant women in the first or second trimester with a diagnosis of iron deficiency anemia. If a subject is eligible, written consent will be obtained by person to person contact. Eligible participants will be randomized to receive either daily oral iron supplementation or every other day oral iron supplementation.
Primary Outcome
Hemoglobin levels will be assessed by blood draw upon enrollment and again in the third trimester of pregnancy
Interventions
- DRUG Ferrous sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2024-01-12 |
| Phase | Phase 4 |
Why NCT04594070 stopped before completion
NCT04594070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Ferrous sulfate is the first listed.
NCT04594070 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04594070 about?
NCT04594070 is a clinical study titled "Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy". The target population for our study is pregnant women in the first or second trimester with a diagnosis of iron deficiency anemia. If a subject is eligible, written consent will be obtained by person to person contact. Eligible participants will be randomized to receive either daily oral iron supple...
What is the current status of trial NCT04594070?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2020-10-27. Estimated completion is 2024-01-12.
What interventions are being tested in trial NCT04594070?
The interventions under investigation include: Ferrous sulfate (DRUG).
Who is sponsoring clinical trial NCT04594070?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04594070's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy